Cristina Gasparetto, MD, Duke Cancer Institute
Articles by Cristina Gasparetto, MD, Duke Cancer Institute
Improving Care in Multiple Myeloma: Unmet Needs and Future Directions
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.
Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.
CAR T-Cell Therapy in RRMM: Adverse Event Management
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.
CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
CAR T-Cell Therapy: CARTITUDE-1 Study and the Role of Cilta-Cel in RRMM
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.
Selection and Sequencing Of Bispecific Antibodies in RRMM and Key Takeaways
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.
Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Shared insight on the adverse event profiles of novel bispecific antibody therapies, with specific focus on how CRS can be adequately managed by the health care team.
Talquetamab, Cevostamab and Elranatamab in RRMM
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD After reviewing other novel bispecific antibodies including talquetamab, cevostamab, and elranatamab in RRMM, panelists consider how these agents compare and might be selected for specific patients.
Transplant-Ineligible NDMM: MAIA Study and SWOG-S0777 Studies
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.
Role of Maintenance Therapy and Key Takeaways in Transplant-Eligible NDMM
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.
Transplant-Eligible NDMM: Optimal Duration of Treatment
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
Transplant-Eligible NDMM: Assessing Response to Therapy and Role of MRD Negativity
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.
Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.
Evaluating Frontline Treatment Strategies in NDMM: The DETERMINATION Trial
ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.
Investigational Agents for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.
Using CAR T Therapy for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.
Role of BCMA-Targeted Agents in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.
Treatment of Relapsed/Refractory Myeloma: Novel Agents
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.
PI-Based Combinations for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
Using IMiD-Based Strategies for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.
Approaching Treatment of Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.
Role of MRD Assessment in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.
Improving Maintenance Therapy for Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
High-Risk Multiple Myeloma: Selecting Initial Therapy
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.
Standard Induction for Newly Diagnosed Symptomatic Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.
Overview of Newly Diagnosed Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.
Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.
Using IMiD-Based Strategies for Relapsed Myeloma
CAR T-Cell Therapy in RRMM: Adverse Event Management
Improving Maintenance Therapy for Myeloma
Improving Care in Multiple Myeloma: Unmet Needs and Future Directions
CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM
Treatment of Relapsed/Refractory Myeloma: Novel Agents